Skip to main content

Table 1 Baseline disease characteristics (Calabresi et al. [5])

From: Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

Characteristic Placebo Peginterferon beta-1a
Every 4 weeks Every 2 weeks
All patients, n 500 500 512
Relapses in the 12 months prior to enrolment, mean (SD) 1.6 (0.67) 1.5 (0.62) 1.6 (0.67)
Baseline EDSS score, mean (SD) 2.44 (1.18) 2.48 (1.24) 2.47 (1.26)
T2 lesions at baseline
 Patients with available data, n 497 499 511
 Mean number of lesions (SD) 50.6 (35.7) 51.4 (36.0) 48.7 (36.8)
 Patients with no T2 lesions at baseline, n (%) 0 3 (<1) 4 (<1)
Gd + lesions at baseline
 Patients with available data, n 497 498 510
 Mean number of lesions (SD) 1.6 (3.8) 1.8 (5.4) 1.2 (3.4)
 Patients with no Gd + lesions at baseline, n (%) 296 (59.6) 297 (59.6) 334 (65.5)
  1. EDSS expanded disability status scale, Gd+ gadolinium-enhancing lesions, SD standard deviation